Regeneron CFO Robert Landry to retire
Regeneron Pharmaceuticals (NASDAQ:REGN) on Friday said Robert Landry, Executive Vice President, Finance and Chief Financial Officer of the company, will retire in February 2024.
Christopher Fenimore, current Senior Vice President, Head of Accounting and Controller at Regeneron, will succeed Landry as CFO upon his retirement.
Fenimore joined Regeneron in 2003 and currently holds global responsibility for U.S. Securities and Exchange Commission reporting, accounting and accounting operations, as well as internal control over financial reporting, accounts payable and payroll.
Source: Press Release



More on Regeneron Pharmaceuticals

Seeking Alphaâs Quant Rating on Regeneron Pharmaceuticals
Historical earnings data for Regeneron Pharmaceuticals
Financial information for Regeneron Pharmaceuticals
Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening
Canaccord ups Regeneron to buy, sees high-dose Eylea re-igniting sales
Regeneron, J&J receive millions to develop new COVID therapies
With two approvals in one day, Regeneron could be headed higher
Regeneron high-dose Eylea gains FDA approval